• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA considers another Philips ventilator recall serious

FDA considers another Philips ventilator recall serious

January 27, 2022 By Sean Whooley

Philips Trilogy Ventilator
[Image from Philips/FDA]
The FDA has identified another recall at Royal Philips‘ (NYSE:PHG) Respironics business as Class I, the most serious kind.

Philips said last summer that it was no longer taking orders of sleep therapy systems as it handled an earlier recall, which may knock it out of the sleep therapy market for a year.

The FDA classified the company’s recall of the DreamStation continuous positive airway pressure (CPAP) devices as Class I, the most serious kind, in July 2021 as a result of polyester-based polyurethane (PE-PUR) sound abatement foam breaking down, allowing for the potential for the foam to enter a device’s air pathway, causing a host of health problems and toxic carcinogenic effects for the user.

Along with supply chain issues, the Respironics recall adversely affected Philips’ fourth-quarter earnings, which it confirmed earlier this week.

The latest recall — initiated by Philips on Dec. 21, 2021 — covers Philips’ Trilogy Evo ventilator and the repair kits for the Trilogy Evo’s muffler assembly. Affected devices were manufactured and distributed between April 15, 2021, and May 24, 2021. To date, 215 ventilators and 51 repair kits have been recalled in the U.S.

FDA said in a notice that the reason for the recall again centers around the PE-PUR foam, with lab testing of the Trilogy Evo identifying the issue. Ventilators with non-conforming foam were distributed to customers in the U.S. and Korea, but the company has reported no injuries or death to date.

Philips’ Trilogy Evo is suitable for continuous or intermittent positive airway pressure ventilation for pediatric through adult patients in institutional, home and non-emergency transport settings. It may be used for invasive and non-invasive ventilation.

Trilogy 100 and 200 ventilators were previously recalled in June 2021 due to the same risk. Certain other Trilogy models — Evo O2, EV300 and Evo Universal — are not affected by the issue and are not included in the recall.

Filed Under: Business/Financial News, Featured, Food & Drug Administration (FDA), News Well, Recalls, Regulatory/Compliance, Respiratory Tagged With: FDA, Philips

More recent news

  • Medtronic reports first patient treated in study of multi-organ denervation for hypertension
  • Baxter turns to an automation company for its new CEO
  • Pristine Surgical appoints new CFO
  • Boston Scientific wins expanded FDA nod for Farapulse PFA
  • FDA warns on issue with J&J Abiomed pump controllers related to 3 deaths

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy